Altimmune expanded AdCOVIDル manufacturing collaboration with Lonza
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under…
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under…
On Mar. 11, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…
On Mar. 11, 2021, the Israel Ministry of Health (MOH), Pfizer and BioNTech announced real-world evidence demonstrating dramatically…
On Mar. 11, 2021, the Department of Veterans Affairs (VA) announced that it had received compassionate use approval…
On Mar. 10, 2021, the U.S. Department of Defense (DOD) announced that it had identified additional personnel authorized…
On Mar. 10, 2021, TGen, an affiliate of City of Hope, announced the start of a scientific study…
On Mar. 10, 2021, CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines announced a partnership to…
On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its…
On Mar. 9, 2021, the NIH announced that approximately two years after establishing a human cerebral organoid system…
On Mar. 9, 2021, Agilent Technologies announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit…
On Mar. 9, 2021, NanoViricides announced that NV-CoV-2 and NV-CoV-2-R were found to be highly effective against a…
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgebackメs Phase 2a randomized, double-blind, placebo-controlled…
On Mar. 5, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
On Mar. 5, 2021, Cue Health announced it had received Emergency Use Authorization (EUA) from the U.S. Food…
On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacメs COVID-19 vaccine…
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVaxル (heat stable COVID-19 vaccine program)…
On Mar. 3, 2021, TGen, an affiliate of City of Hope announced that an in-depth analysis of the…
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
On Mar. 2, 2021, the NIH announced that it had launched a research effort to understand how SARS-CoV-2,…
On Mar. 2, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with Merck’s Ervebo was…
On Mar. 2, 2021, MediciNova announced it that given the COVID-19 vaccines currently in use and other vaccines…
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…